AstraZeneca and Chi-Med』s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification
Susan Galbraith, Head of Oncology, AstraZeneca Research and Early Development, said: 「We are committed to developing innovative medicines to overcome the key drivers of cancer mechanisms of resista......